Russian pharma facing barriers abroad and at home

Obstacles standing in the way of successful launches of Russian products to international pharma markets have been highlighted by trade group the Association of Russian Pharmaceutical Manufactures (ARPM) following industry meetings.

Medical import substitution and quality control in producing Russian medicines have long been a priority in the sector, which continues to struggle to make headway in markets abroad.

Highlighting some of the problems, ARPM general director Viktor Dmitriev, said: “First of all, our regulatory internal procedures are not always harmonized with the relevant procedures in foreign countries.